SMAD2 and pulmonary arterial hypertension: In summary, a clear PAH pathogenetic model emerges: BMPR2-mediated antiproliferative signaling is reduced, while the ActRIIA-SMAD2 pathway gains prominence, leading to vascular remodeling through its pro-proliferative effects [11].